Credit Analysis: Ward & Snape Limited (05278527)

1. Credit Opinion: CONDITIONAL

Rationale: Ward & Snape Limited presents a mixed credit profile that warrants caution. While the company has a 20-year trading history in the relatively defensive dental/medical sector and maintains a positive net asset position, the most recent financial year (to October 2025) shows a sharp deterioration in balance sheet strength. Net assets fell by approximately 56% (£98,191 → £43,049), total assets declined by 59%, and headcount was reduced from 10 to 6 employees. These are significant contraction signals.

The company files as a micro-entity, meaning financial disclosure is minimal — no profit and loss account is filed at Companies House, limiting visibility into trading performance, margins, and cash generation. An outstanding director's loan of £20,049 (down from £51,349) sits within current assets, which inflates the apparent liquidity position.

Any credit facility should be conditioned on: - Full management accounts and cash flow forecasts for the current trading period - A satisfactory explanation for the asset contraction and headcount reduction in FY2025 - Personal guarantees from the PSCs (Xxxxxx Xxxxxxxxname shown to subscribers and Xxxxxx Xxxxxxxxname shown to subscribers, both holding 75%+ control) - Security where available, noting fixed assets are negligible at £1,560

2. Financial Strength

Balance Sheet Health: Moderately Weak and Declining

The balance sheet is small in absolute terms and has contracted materially. While liabilities have been reduced (a positive sign of de-leveraging), the simultaneous collapse in assets suggests funds have been withdrawn from the business rather than reinvested. The director's loan repayment of £31,300 during the year partially explains this outflow.

The company holds negligible fixed assets (£1,560), meaning there is virtually no tangible security available to a lender. The asset base is almost entirely current assets, and a significant portion (£20,049) is a director's loan receivable — an asset of questionable realisable value in a distress scenario.

Net assets remain positive, and the company is solvent, but the cushion is thin. A further year of similar contraction would push net assets toward break-even.

Historical Context: The company demonstrated strong growth from FY2020 (£5,351 net assets) through FY2024 (£98,191), suggesting the business was on an upward trajectory before the FY2025 reversal. Whether this reversal is a temporary setback or the beginning of a sustained decline is the critical question.

3. Cash Flow Assessment

Liquidity: Adequate on Paper, Weaker on Closer Inspection

The headline current ratio of approximately 2.8x (£66,152 current assets vs £23,489 current liabilities) appears healthy. However, this requires adjustment:

• Director's loan adjustment: Removing the £20,049 director's loan receivable reduces current assets to approximately £46,103 and the current ratio to ~1.96x. Director loans are not commercial receivables — they are unlikely to be recovered on demand in a distress scenario.
• Accruals and deferred income: A further £4,513 in accruals and deferred income represents obligations that will crystallise.

On an adjusted basis, the effective working capital buffer is closer to £21,540 — still positive but considerably thinner than the headline figure suggests.

Working Capital Trend: The 54% reduction in working capital year-on-year is the most concerning metric. This could reflect: - Reduced trade debtors (possible contraction in revenue) - Cash withdrawals for director loan repayment - Reduced inventory levels

Without a filed P&L, it is impossible to determine whether the company is profitable at the trading level. The headcount reduction from 10 to 6 suggests either cost-cutting in response to lower revenue or operational restructuring.

Cash generation capacity is uncertain. The dental/medical sector typically generates steady cash flows, but the scale of this business (micro-entity, 6 employees) means the absolute cash generation is modest and vulnerable to client concentration risk.

4. Monitoring Points

If credit is extended, the following should be monitored:

1. Net Asset Trajectory: Track whether FY2025's contraction continues or stabilises. A further decline below £25,000 would trigger concern; below £15,000 would indicate critical thinning of the equity buffer.

2. Director's Loan Balance: The loan is being repaid (£31,300 in FY2025, £26,621 in FY2024), which is positive. Monitor that repayments continue and no new advances are drawn. Any increase in the director's loan balance would be a red flag.

3. Headcount and Revenue Indicators: The 40% staff reduction is significant. Seek confirmation of whether this reflects operational efficiency gains or revenue contraction. Request monthly or quarterly turnover figures.

4. Current Ratio Maintenance: Ensure the adjusted current ratio (excluding director's loan) remains above 1.5x. Deterioration below this threshold would indicate weakening short-term liquidity.

5. Filing Compliance: Accounts are currently up to date (next due July 2027). Confirmation statements are current. Maintain watch for any filing delays, which could signal administrative distress.

6. Creditor Payment Behaviour: Monitor trade creditor days. The reduction in creditors from £66,343 to £23,489 could indicate either improved payment discipline or reduced purchasing activity — both scenarios have different credit implications.

7. PSC Stability: Four PSCs are listed with overlapping ownership claims. Monitor for any changes in ownership structure, which could signal shareholder disputes or business restructuring.

8. Sector-Specific Risks: Dental practices and dental supply manufacturing face NHS contract pressures, regulatory compliance costs, and competition from larger corporate dental groups. Monitor for any material changes in the regulatory or commissioning environment.

Names of the people mentioned are shown to subscribers. See subscription